The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Teva Pharmaceutical Industries (TEVA - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Teva Pharmaceutical Industries is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TEVA is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for TEVA's full-year earnings has moved 11.74% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, TEVA has returned 27.39% so far this year. Meanwhile, the Medical sector has returned an average of 2.56% on a year-to-date basis. This means that Teva Pharmaceutical Industries is performing better than its sector in terms of year-to-date returns.
Looking more specifically, TEVA belongs to the Medical - Generic Drugs industry, a group that includes 26 individual stocks and currently sits at #180 in the Zacks Industry Rank. Stocks in this group have gained about 4.10% so far this year, so TEVA is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TEVA as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Is Teva Pharmaceutical Industries (TEVA - Free Report) one of those stocks right now? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Teva Pharmaceutical Industries is a member of the Medical sector. This group includes 761 individual stocks and currently holds a Zacks Sector Rank of #7. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. TEVA is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for TEVA's full-year earnings has moved 11.74% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, TEVA has returned 27.39% so far this year. Meanwhile, the Medical sector has returned an average of 2.56% on a year-to-date basis. This means that Teva Pharmaceutical Industries is performing better than its sector in terms of year-to-date returns.
Looking more specifically, TEVA belongs to the Medical - Generic Drugs industry, a group that includes 26 individual stocks and currently sits at #180 in the Zacks Industry Rank. Stocks in this group have gained about 4.10% so far this year, so TEVA is performing better this group in terms of year-to-date returns.
Going forward, investors interested in Medical stocks should continue to pay close attention to TEVA as it looks to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on TEVA - FREE